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Abstract
Lately, there has been an increased incidence of late stent thrombosis; especially following Drug eluting stent
(DES) implantation. Several factors are associated with an increased risk of stent thrombosis, including the proce-
dure itself, patient and lesion characteristics, stent design, and premature cessation of anti-platelet drugs. We pre-
sent a case of late stent thrombosis (LST) following DES implantation after a period of 68 months, making it the
longest reported case of LST reported in the literature, despite the use of dual anti-platelet therapy.
Introduction
Several randomized clinical trials have shown that
implanting Drug eluting stents (DES) result in clinically
significant reductions of in-stent re-stenosis compared
with Bare metal stents (BMS) [1,2]. However increased
risk of Late Stent thrombosis (LST) is more pronounced
6 months to 1 year after DES implantation, compared
with BMS [3-5]. The benefits of lower rate of in-stent
re-stenosis versus the risk of in-stent thrombosis is
paramount in the decision making process especially
when faced with a patient requiring emergency stenting.
In-stent thrombosis is a much rarer event than in-stent
re-stenosis but results in mortality rate of up to 45%
and a nonfatal infarction rate of another 30% to 40%
[6,7]. Our patient experienced very late stent thrombo-
sis, occurring 68 months post DES implantation, making
it the longest time-to-event, reported in the literature.
Case presentation
A 75-year-old Caucasian gentleman had presented to
our emergency department 5 years and 8 months ago
(2003) with chest pain secondary to anterior wall ST-
segment elevation myocardial infarction. His past medi-
cal history was significant for hypertension and dyslipi-
demia with a 50 pack years smoking history. Dual oral
anti-platelet therapy with aspirin and clopidogrel along
with intravenous heparin were administered. Emergent
left heart catheterization and selective coronary angio-
graphy revealed thrombotic 90% occlusion of the mid
left anterior descending coronary artery. Balloon angio-
plasty and thombectomy were performed. A sirolimus
eluting stent (3.0 × 33) was placed at maximum pressure
of 10 atmospheres across the lesion. Angiography after
stent deployment showed complete expansion of the
stent with grade 3 TIMI flow, without proximal or distal
edge dissections or any residual stenosis. The patient
received intravenous abciximab bolus and infusion ther-
apy for 12 hours and had an uneventful hospital course.
Subsequently, the patient had been strictly compliant
with dual antiplatelet therapy of aspirin and clopidogrel.
However about three weeks prior to this admission
(2009), he had two mild episodes of angina on exertion.
A persantine-technetium 99 myocardial perfusion ima-
ging stress test carried out was interpreted as positive
for anterior wall reversible ischemia. Few days later, he
presented to our hospital with sudden onset chest tight-
ness and an EKG showing ST-segment elevation in
leads V1-2. Emergent coronary angiography revealed a
filling defect with 100% occlusion in the mid segment of
the previous LAD stent with TIMI-0 flow, consistent
with in-stent thrombosis along with significant proximal
in-stent restenosis (Figure 1). Intravenous bivalirudin
and eptifibatide were administered. Balloon angioplasty
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olimus RX stent (3.0 × 15) was placed across the lesion
resulting in 0% residual stenosis. Another Everolimus
RX stent (3.0 × 23) was deployed at the proximal edge
of the previous stent and a smaller Everolimus RX stent
(3.0 × 8) was deployed in an 80% de-novo lesion leaving
no residual stenosis (Figure 2). Peak plasma troponin
level was 60.05 ng/ml. A transthoracic echocardiogram
performed after 48 hours showed mild hypokinesis of
anterior wall of the left ventricle, an estimated ejection
fraction of 45%. After 3 days of hospitalization patient
was discharged on daily medications of aspirin 325 mg
daily and clopidogrel 75 mg daily, atorvastatin 80 mg,
isosorbide mononitrate 30 mg daily, atenolol 50 mg
daily and lisinopril 20 mg daily.
Discussion
Stent thrombosis (ST) is classified by Academic
Research Consortium into four types based on the time
of event as; Acute: within 24 hours, Subacute: 24 hours
to 30 days, Late: after 30 days, and very late: after 12
months. The consequences of ST could be catastrophic
with a mortality rate of 45%, with the majority of others
suffering nonfatal myocardial infarction [6,7]. Angio-
scopic and optical coherence tomography studies have
shown that lack of complete endothelialization of DES
to be the most important predictor of LST [8,9]. Vir-
mani et al have confirmed the same mechanism using
human pathological data [10]. Risk factors for LST
include patient and lesion characteristics, non-compli-
ance of anti-platelet drugs and procedural factors like
incomplete stent apposition, number and the length of
stents, coronary dissection, etc. [11]. It has been
reported that the risk of stent thrombosis up to 4 years
is significantly higher if the DES was placed during ACS
[12]. In the setting of myocardial infarction, underlying
plaque morphology may affect the rate of healing, when
stent struts penetrate deeply into a necrotic core and
are not in contact with cellular areas, which impairs
stent endothelialization [13]. A large thrombus burden
in the setting of ST-segment elevation myocardial
infarction is a risk factor for future stent thrombosis
[14]. Hypercholesterolemia has recently been shown to
cause endothelial progenitor cell dysfunction, thus
Figure 1 Angiographic evidence of in-stent thrombosis in the mid-segment of previous LAD stent.
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to the significance of statin therapy after PCI [15].
There is consensus among cardiologists that stent
endothelialization starts from the edges towards the cen-
ter of the stent, leaving the middle portion of the stent
to be the last to be covered by endothelium and usually
t h em o s tl i k e l ys i t ef o rL S T[ 1 0 ] .T h es a m ea u t h o r s
reported LST to be associated with diffuse in stent re-
stenosis. The following factors could have contributed
to the development of in-stent thrombosis in our
patient: long stent [33 mm in length], history of
hypercholesterolemia, implantation of DES emergently
during ST-segment myocardial infarction with high
thrombus burden necessitating rheolytic thrombectomy
and the presence of in-stent re-stenosis.
The 2007 ACC/AHA/SCAI focused update of the
2005 guidelines on PCI recommended dual antiplatelet
therapy with aspirin and a theinopyridine for at least
12 months after DES implantation. Recent reports of
very late in-stent thrombosis of DES long years after
implantation represent a growing evidence to continue
dual antiplatelet therapy for a longer period of time,
perhaps indefinitely given the devastating consequences
of in-stent thrombosis. A retrospective observational
trial has suggested that triple antiplatelet therapy using
aspirin, clopidogrel and cilostazol may further reduce
the risk of stent thrombosis especially in patients or
lesions at increased risk with no difference in the rate
of major bleeding [16]. The advent of prasugrel as a
more potent platelet inhibitor compared to clopidrogrel
may decrease the long term adverse cardiovascular
events [17]. Finally, this case highlights the need of
further long-term studies on the occurrence of very
late in-stent restenosis in patients treated with DES,
both as an independent factor, and as predisposing to
very late stent thrombosis.
Consent
Written informed consent was obtained from the
patient’s next of kin/family for publication of this case
report. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Figure 2 Angiographic evidence of blood flow (TIMI-3) in the mid-LAD segment post stenting.
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ACS: acute coronary syndrome; BMS: bare metal stent; DES: drug eluting
stent; LST: late stent thrombosis; PCI: per cutaneous intervention.
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